SCHEMBL7213175

SCHEMBL7213175

COc1ccc(NS(=O)(=O)c2ccccc2F)c(C(=O)Nc2ccc(Cl)c(Cl)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC20A2 Q08357 1/20 0.54
SLC20A1 Q8WUM9 1/20 0.54
MAPT P10636 7/20 0.53
KMT2A Q03164 7/20 0.53
ALDH1A1 P00352 6/20 0.53
MEN1 O00255 6/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
LMNA P02545 4/20 0.53
HTT P42858 4/20 0.53
HPGD P15428 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
KDM4E B2RXH2 2/20 0.49
GAA P10253 2/20 0.49
FBP1 P09467 1/20 0.49
AVPR2 P30518 1/20 0.49
GPR27 Q9NS67 1/20 0.49
POLB P06746 2/20 0.45
RECQL P46063 1/20 0.45
PNLIP P16233 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7208708 0.86 GPR27 (0.63) SLC20A2SLC20A1MAPTKMT2AALDH1A1
SCHEMBL7123072 0.86 KMT2A (0.58) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL7533748 0.78 CCR2 (0.53) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL7538052 0.76 SMN1; SMN2 (0.56) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL27926737 0.75 SLC20A2 (0.58) SLC20A2SLC20A1MAPTKMT2AALDH1A1
SCHEMBL7208733 0.75 SLC10A6 (0.71) SLC20A2SLC20A1MAPTKMT2AALDH1A1
SCHEMBL7117455 0.74 SLC10A2 (0.60) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL7128109 0.74 MEN1 (0.64) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL7563545 0.74 CCR2 (0.48) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL21708250 0.72 ALDH1A1 (0.57) MAPTKMT2AALDH1A1MEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1187531-A4 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2003-05-28 EP claimed
US-6458845-B1 METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A SMITHKLINE BEECHAM CORPORATION 2002-10-01 US claimed
EP-1187531-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-03-20 EP claimed
WO-2001098264-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-12-27 WO claimed
WO-2000078145-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-28 WO claimed
EP-1187531-A4 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2003-05-28 EP disclosed
US-6458845-B1 METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A SMITHKLINE BEECHAM CORPORATION 2002-10-01 US disclosed
EP-1187531-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-03-20 EP disclosed
WO-2000078145-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-28 WO disclosed